RT @drdavidliew: Tocilizumab in GCA - three year data from GiACTA on steroid exposure and time to flare: - steroid-spari
Tweet Content
Tocilizumab in GCA - three year data from GiACTA on steroid exposure and time to flare:
- steroid-sparing benefit persists in both new-onset and relapsing disease
- in avoiding flares, benefit for weekly dosing in both new-onset and relapsing disease
OP0027 #EULAR2020 @RheumNow https://t.co/tGU6ayglHW
Show on Archive Page
On
Display in Search Results
On